Leads Medical science Patients Pharmaceutical 
European Pharmaceutical Review
MAY 2, 2023
Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. 3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. 1,2 In the EU, an estimated 2.7
Contrarian Sales Techniques
DECEMBER 5, 2023
Did you know that a well-trained pharmaceutical sales rep can be the driving force behind a healthcare provider's decision-making process? In the complex world of pharmaceuticals, it’s not just what you sell, but how you sell it. In this post, we’re diving deep into the realm of pharmaceutical sales training. That’s right.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 19, 2022
That statement, coined by one of my colleagues at Healthware MedComms , summarises the changing state of communications between pharmaceutical organisations and their healthcare provider (HCP) stakeholders. No doctor wakes up in the morning asking what your brand can do for them.
pharmaphorum
NOVEMBER 17, 2022
As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important. That’s the role of the pharmaceutical companies that employ MSLs and their partners who help to design engaging education platforms and curricula in order to best prepare these important communicators.
Veeva
FEBRUARY 6, 2022
This engagement is continuing to remain high, with evolving requirements and preferences of healthcare practitioners (HCPs) in the ways they engage with pharma reps and medical science liaisons (MSLs) through virtual communications. Five steps to closing the CX gap with HCPs and Patients. Get stakeholder buy in on the “why”.
European Pharmaceutical Review
DECEMBER 28, 2023
Following their introduction, these therapies have moved to early lines of treatment, but unfortunately, a significant number of patients are not cured with these approaches. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.
PM360
NOVEMBER 29, 2022
Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. The solution may lie in another technology that is already being used successfully by other areas of the life sciences organization: artificial intelligence (AI).
Expert insights. Personalized for you.
99 
Let's personalize your content